The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
Open accessAbstract
Background Standardized conditions to distinguish subpopulations of colorectal cancer (CRC) patients more and less sensitive to cetuximab therapy remain undefined.Materials and methods We retrospectively analyzed epidermal growth factor receptor (EGFR) copy number by fluorescence in situ hybridization (FISH) in paraffin-embedded tumor blocks from 85 chemorefractory CRC patients treated with cetuximab. Results were analyzed according to different score systems previously reported in colorectal and lung cancers. The primary end point of the study was identification of the EGFR FISH score that best associates with response rate (RR).Results Using receiver operating characteristic (ROC) analysis, the cut-off that best discriminated responders versus nonresponders to cetuximab was a mean of 2.92 EGFR gene copies per cell. This model showed sensitivity of 58.6% [95% confidence interval (CI) = 47.1-70.1) and specificity of 93.3% (95% CI = 80.6-100). EGFR FISH-positive patients (N = 43, 50.6%) had significantly higher RR (P = 0.0001) and significantly longer time to disease progression (P = 0.02) than EGFR FISH negative (N = 42, 49.4%). Other scoring systems resulted less accurate in discriminating patients with the highest likelihood of response to cetuximab therapy.Conclusions CRC patients with high EGFR gene copy number have an increased likelihood to respond to cetuximab therapy. Prospective clinical trials with a careful standardization of assay conditions and pattern interpretation are urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased EGFR gene copy number could predict response among KRAS wild-type patients [53, 91, 111-113]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationJemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citation
Cited by
Sorted by citations
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
“• The usefulness of anti-EGFR antibody drugs has been reported in metastatic colorectal cancer without KRAS gene mutations [38–41, 47, 53, 55, 85–90].”
BackgroundEpidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Itabashi, M., Shimada, Y., Tanaka, S., Ito, Y., Ajioka, Y., Hamaguchi, T., Hyodo, I., Igarashi, M., et al. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0315-2 · Cited by 706
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 544
Systemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 526
NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death
Huang, D., Chen, J., Yang, L., Ouyang, Q., Li, J., Lao, L., Zhao, J., Liu, J., Lu, Y., Xing, Y., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0207-y · Cited by 445
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436
Self-citationPerrone, F., Lampis, A., Orsenigo, M., Di Bartolomeo, M., Gevorgyan, A., Losa, M., Frattini, M., Riva, C., Andreola, S., Bajetta, E., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn541 · Cited by 410
Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., Masi, G., Graziano, F., Cremolini, C., Rulli, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2796 · Cited by 403
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 287
Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., Martini, M., Cipani, T., Marrapese, G., Mazzucchelli, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007287 · Cited by 259
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J., D'Hondt, L. A., Strauven, T., Chaskis, C., Veld, P. I. '., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 260
Santini, D., Loupakis, F., Vincenzi, B., Floriani, I., Stasi, I., Canestrari, E., Rulli, E., Maltese, P. E., Andreoni, F., Masi, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0181 · Cited by 234
van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0795 · Cited by 232
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 241
Licitra, L. F., Mesı́a, R., Rivera, F., Remenár, É., Hitt, R., Erfan, J., Rottey, S., Kawecki, A., Zabolotnyy, D., Benasso, M., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq588 · Cited by 226
Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A., & Eckhardt, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8168 · Cited by 217
Self-citationEGFR Signaling in Colorectal Carcinoma
Krasinskas, A. M. (2011) · Pathology Research International · doi:10.4061/2011/932932 · Cited by 200
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
Cappuzzo, F., Varella-Garcia, M., Finocchiaro, G., Skokan, M., Gajapathy, S., Carnaghi, C., Rimassa, L., Rossi, E., Ligorio, C., Di Tommaso, L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604439 · Cited by 178
Self-citationMohan, S., Heitzer, E., Ulz, P., Lafer, I., Lax, S., Auer, M., Pichler, M., Gerger, A., Eisner, F., Höefler, G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004271 · Cited by 178
Modjtahedi, H., & Essapen, S. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283330590 · Cited by 177
Personeni, N., Fieuws, S., Piessevaux, H. H., Hertogh, G. D., Schutter, J. D., Biesmans, B., Roock, W. D., Capoen, A., Dêbiec‐Rychter, M., Laethem, J. V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0449 · Cited by 176
Licitra, L. F., Störkel, S., Kerr, K. M., Cutsem, E. V., Pirker, R., Hirsch, F. R., Vermorken, J. B., von Heydebreck, A., Esser, R., Celik, I., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.018 · Cited by 167
Self-citationA Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy
Deschoolmeester, V., Baay, M. F. D., Specenier, P. M., Lardon, F., & Vermorken, J. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0025 · Cited by 172
Martin, V, Landi, L., Molinari, F., Fountzilas, G., Geva, R., Riva, A., Saletti, P., De Dosso, S., Spitale, A., Tejpar, S., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.4 · Cited by 156
Self-citationMolinari, F., Felicioni, L., Buscarino, M., De Dosso, S., Buttitta, F., Malatesta, S., Movilia, A., Luoni, M., Boldorini, R., Alabiso, O., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3137 · Cited by 159
Detection of KRAS and BRAF Mutations in Colorectal Carcinoma
Arcila, M. E., Lau, C., Nafa, K., & Ladanyi, M. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.005 · Cited by 138
Han, S.-W., Oh, D.-Y., Im, S., Park, S. R., Lee, K.-W., SONG, H. S., Lee, N. S., Lee, K. H., Choi, I. S., Lee, M. H., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604861 · Cited by 137
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
“Furthermore, it has been demonstrated in several clinical trials that patients with mCRC and a KRAS mutation do not respond to cetuximab therapy (Lievre et al., 2006; Benvenuti et al., 2007; Di Fiore et al., 2007; Khambata-Ford et al., 2007; Cappuzzo et al., 2008; De Roock et al., 2008; Karapetis et al., 2008).”
BackgroundMutations and Response to Epidermal Growth Factor Receptor Inhibitors
Laurent‐Puig, P., Lièvre, A., & Blons, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0905 · Cited by 134
Molinari, F., Martin, V, Saletti, P., De Dosso, S., Spitale, A., Camponovo, A., Bordoni, A., Crippa, S., Mazzucchelli, L., & Frattini, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604848 · Cited by 122
Yonesaka, K., Zejnullahu, K., Lindeman, N. I., Homes, A. J., Jackman, D. M., Zhao, F., Rogers, A. M., Johnson, B. E., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0957 · Cited by 121
Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010445 · Cited by 117
Shalaby, A., Presneau, N., Ye, H., Halai, D., Berisha, F., Idowu, B. D., Leithner, A., Liegl, B., Briggs, T. W. R., Bácsi, K., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2818 · Cited by 117
Chen, L. F., Cohen, E. E. W., & Grandis, J. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2318 · Cited by 120
Cao, X., Chen, J., Li, B., Dang, J., Zhang, W., Zhong, X., Wang, C., Raoof, M., Sun, Z., Yu, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl9171 · Cited by 120
Italiano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., Gugenheim, J., Becouarn, Y., Brunet, R., Fonck, M., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0864-z · Cited by 114
Oncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117
Treatment in advanced colorectal cancer: what, when and how?
Chau, I., & Cunningham, D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605061 · Cited by 115
Tabernero, J., Cervantes, A., Rivera, F., Martinelli, E., Rojo, F., von Heydebreck, A., Macarulla, T., Rodriguez-Braun, E., Eugenia Vega-Villegas, M., Senger, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6043 · Cited by 110
Self-citationEGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy
Milanezi, F., Carvalho, S., & Schmitt, F. C. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.4.417 · Cited by 109
Baker, J. B., Dutta, D., Watson, D., Maddala, T., Munneke, B., Shak, S., Rowinsky, E. K., Xu, L.-A., Harbison, C. T., Clark, E. A., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606054 · Cited by 110
Vecchione, L., Jacobs, B., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.021 · Cited by 109
Self-citationCustodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 100
André, T., Blons, H., Mabro, M., Chibaudel, B., Bachet, J., Tournigand, C., Bennamoun, M., Artru, P., Nguyen, S., Ebenezer, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds465 · Cited by 95
Yeo, D. M., Oh, S. N., Jung, C., Lee, M. A., Oh, S. T., Rha, S. E., Jung, S. E., Byun, J. Y., Gall, P., & Son, Y. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24541 · Cited by 91
Bengala, C., Bettelli, S. R., Bertolini, F., Salvi, S., Chiara, S., Sonaglio, C., Losi, L., Bigiani, N., Sartori, G., Dealis, C., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn647 · Cited by 87
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
oden-Gangloff, A., Fiore, F. D., Bibeau, F., Lamy, A., Bougeard, G., Charbonnier, F., Blanchard, F., Tougeron, D., Ychou, M., Boissière‐Michot, F., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605008 · Cited by 90
Watanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., Iinuma, H., Shibuya, H., & Eshima, K. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31821d37a3 · Cited by 82
Perner, S., Wagner, P., Soltermann, A., Lafargue, C. J., Tischler, V., Weir, B. A., Weder, W., Meyerson, M. M., Giordano, T. J., Moch, H., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2443 · Cited by 81
Stintzing, S., Kapaun, C., Laubender, R. P., Jung, A., Neumann, J. H. L., Modest, D. P., Giessen, C. A., Moosmann, N., Wollenberg, A., Kirchner, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27654 · Cited by 83
Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76
Molecular Markers in the Treatment of Metastatic Colorectal Cancer
Wilson, P. M., LaBonte, M. J., & Lenz, H. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181e07738 · Cited by 79
Spindler, K.-L. G., Pallisgaard, N., Rasmussen, A. A., Lindebjerg, J., Andersen, R. F., Crüger, D. G., & Jakobsen, A. K. M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn712 · Cited by 78
Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation
Fessler, E., & Medema, J. P. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.008 · Cited by 81
Scartozzi, M., Bearzi, I., Mandolesi, A., Pierantoni, C., Loupakis, F., Zaniboni, A., Negri, F., Quadri, A., Zorzi, F., Galizia, E., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-303 · Cited by 72
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
Fiore, F. D., Sesboüé, R., Michel, P., Sabourin, J., & Frébourg, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606008 · Cited by 76
Rivera, M., Fichtner, I., Wulf-Goldenberg, A., Sers, C., Merk, J., Patone, G., Merve, K., Kanashova, T., Mertins, P., Hoffmann, J., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.11.005 · Cited by 72
Park, J. H., Han, S., Oh, D., Im, S., Jeong, S., Park, K. J., Kim, T., Bang, Y., & Park, J.-G. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1586-z · Cited by 72
Role of targeted agents in metastatic colorectal cancer
Prenen, H., Vecchione, L., & Cutsem, E. V. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0281-x · Cited by 70
Predictive and Prognostic Markers in Colorectal Cancer
George, B., & Kopetz, S. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0162-3 · Cited by 66
Jiang, Z., Li, C., Li, F., & Wang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056205 · Cited by 67
Linking somatic genetic alterations in cancer to therapeutics
Stuart, D. D., & Sellers, W. R. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.02.001 · Cited by 66
Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors
Gilbert, J. A., Adhikari, L., Lloyd, R. V., Rubin, J., Haluska, P., Carboni, J. M., Gottardis, M. M., & Ames, M. M. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0318 · Cited by 65
Egloff, A. M., & Grandis, J. R. (2009) · Journal of Oncology · doi:10.1155/2009/896407 · Cited by 64
Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva
Gadducci, A., Tana, R., Barsotti, C., Guerrieri, M. E., & Genazzani, A. R. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.09.003 · Cited by 62
Targeted therapy of cancer: new roles for pathologists in colorectal cancer
Hamilton, S. R. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.14 · Cited by 61
Cetuximab in the treatment of patients with colorectal cancer
Garrett, C. R., & Eng, C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.582464 · Cited by 60
Imaging EGFR and HER2 by PET and SPECT: A Review
Corcoran, E. B., & Hanson, R. N. (2013) · Medicinal Research Reviews · doi:10.1002/med.21299 · Cited by 61
Kato, S., Okamura, R., Mareboina, M., Lee, S., Goodman, A. M., Patel, S. P., Fanta, P. T., Schwab, R. B., Vu, P., Raymond, V. M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00180 · Cited by 64
Markers of resistance to anti-EGFR therapy in colorectal cancer.
Shaib, W. L., Mahajan, R., & El‐Rayes, B. F. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.029 · Cited by 61
Decreased survival in EGFR gene amplified vulvar carcinoma
Growdon, W. B., Boisvert, S. L., Akhavanfard, S., Oliva, E., Dias-Santagata, D. C., Kojiro, S., Horowitz, N. S., Iafrate, A. J., Borger, D. R., & Rueda, B. R. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.07.038 · Cited by 57
Cuneo, K. C., Nyati, M. K., Ray, D., & Lawrence, T. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.002 · Cited by 57
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
Zlobec, I. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i38.4823 · Cited by 52
Cappuzzo, F., Sacconi, A., Landi, L. M., Ludovini, V., Biagioni, F., D’Incecco, A., Capodanno, A., Salvini, J., Corgna, E., Cupini, S., et al. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.11.006 · Cited by 55
Self-citationHuerta, S., Baay-Guzman, G. J., González-Bonilla, C. R., Livingston, E. H., Huerta‐Yépez, S., & Bonavida, B. (2008) · Nitric Oxide · doi:10.1016/j.niox.2008.11.006 · Cited by 52
Lévi, F., Karaboué, A., Gorden, L. D., Innominato, P. F., Saffroy, R., Giacchetti, S., Hauteville, D., Guettier, C., Adam, R. A., & Bouchahda, M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1327-8 · Cited by 52
Franchi, A., Fondi, C., Paglierani, M., Pepi, M., Gallo, O., & Santucci, M. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2008.12.005 · Cited by 50
Bengala, C., Bettelli, S. R., Bertolini, F., Sartori, G., Fontana, A., Malavasi, N., Depenni, R., Zironi, S., Giovane, C. D., Luppi, G., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605853 · Cited by 49
Perkins, G., Lièvre, A., Ramacci, C., Méatchi, T., de Reyniès, A., Emile, J., Boige, V., Tomasic, G., Bachet, J., Bibeau, F., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25152 · Cited by 54
EGFR amplification and expression in oral squamous cell carcinoma in young adults
COSTA, V. B. B. D., Kowalski, L. P., Coutinho‐Camillo, C. M., Begnami, M. D., Calsavara, V. F., Neves, J. I., & Kaminagakura, E. (2018) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2018.01.002 · Cited by 49
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
Luo, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3858 · Cited by 51
Ålgars, A., Lintunen, M., Carpén, O., Ristamäki, R., & Sundström, J. T. T. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.223 · Cited by 53
Huang, S., Cheng, S., Chien, H., Liao, C., Chen, I., Wang, H., Chuang, W., Wang, C., & Hsieh, L. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.06.511 · Cited by 47
Chua, W. M., Kho, P. S., Moore, M. M., Charles, K. A., & Clarke, S. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.07.012 · Cited by 45
Scartozzi, M., Giampieri, R., Maccaroni, E., Mandolesi, A., Giustini, L., Silva, R., Zaniboni, A., Biscotti, T., Biagetti, S., Galizia, E., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr558 · Cited by 43
Martin, V., Mazzucchelli, L., & Frattini, M. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.059592 · Cited by 46
Metzger, B., Chambeau, L., Begon, D. Y., Faber, C., Kayser, J., Berchem, G., Pauly, M., Boniver, J., Delvenne, P., Dicato, M. A., et al. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-144 · Cited by 48
Pantaleo, M. A., Nannini, M., Maleddu, A., Fanti, S., Nanni, C., Boschi, S., Lodi, F., Nicoletti, G., Landuzzi, L., Lollini, P., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn625 · Cited by 45
Santini, D., Spoto, C., Loupakis, F., Vincenzi, B., Silvestris, N., Cremolini, C., Canestrari, E., Graziano, F., Galluccio, N., Salvatore, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq318 · Cited by 46
Biomarker in Colorectal Cancer
Schirripa, M., & Lenz, H. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000190 · Cited by 47
Molecular Markers for Novel Therapeutic Strategies in Pancreatic Endocrine Tumors
Gilbert, J. A., Adhikari, L., Lloyd, R. V., Halfdanarson, T. R., Muders, M. H., & Ames, M. M. (2012) · Pancreas · doi:10.1097/mpa.0b013e31826cb243 · Cited by 44
Metadata
- Authors
- Cappuzzo, F., Finocchiaro, G., Rossi, E., Jänne, P. A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T., Destro, A., Roncalli, M., Crino, L., Franklin, W. A., Santoro, A., & Varella-Garcia, M.
- Affiliations
- IRCCS Humanitas Research Hospital (IT)
- University of Colorado Cancer Center (US)
- Ospedale Bellaria (IT)
- Policlinico San Matteo Fondazione (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Corresponding author
- Cappuzzo, F.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2008-04
- Volume
- 19
- Issue
- 4
- Pages
- 717-723
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2158475201
- Cited by
- 267
- References
- 39
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 8 · 2015: 12 · 2014: 18 · 2013: 20 · 2012: 24
- FWCI
- 18.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Università degli Studi di Napoli Federico II
- Cancer Center, University of Colorado
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EGFR copy number, cetuximab, colorectal cancer, chemorefractory cancer, predictive biomarkers, treatment response prediction, time to progression, EGFR amplification
- MeSH terms
- Cetuximab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Immunohistochemistry, Italy, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, ROC Curve, Sensitivity and Specificity, Biomarkers, Tumor, Colorectal Neoplasms, Confidence Intervals, Survival Analysis, Treatment Outcome, In Situ Hybridization, Fluorescence, Disease-Free Survival, Patient Selection, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
